We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+26%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$7.24B
AUM Growth
+$829M
Cap. Flow
-$224M
Cap. Flow %
-3.09%
Top 10 Hldgs %
63.72%
Holding
51
New
5
Increased
21
Reduced
4
Closed
9

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$330M
2
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$190M
3
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$130M
4
ARGX icon
argenx
ARGX
+$109M
5
GPCR icon
Structure Therapeutics
GPCR
+$76.4M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$810M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$373M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$100M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$44.6M
5
NUVL
Nuvalent
NUVL
+$39.2M

Sector Composition

Rank Sector Weight
1 Healthcare 94.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRTX
26
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$39.6M 0.55%
+125,000
New +$24.3M
RCKT icon
27
Rocket Pharmaceuticals
RCKT
$387M
$37.8M 0.52%
1,260,900
+10,900
+0.9% +$241K
ARWR icon
28
Arrowhead Research
ARWR
$12.1B
$34.6M 0.48%
1,130,000
+565,000
+100% +$15M
MRNS
29
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$34.2M 0.47%
3,150,000
– –
MNKD icon
30
MannKind Corp
MNKD
$1.25B
$32.8M 0.45%
9,000,000
– –
SLNO
31
DELISTED
Soleno Therapeutics
SLNO
$31.6M 0.44%
+785,000
New +$22.3M
VRCA icon
32
Verrica Pharmaceuticals
VRCA
$92.1M
$29.3M 0.4%
400,000
+104,594
+35% +$4.3M
IMGN
33
DELISTED
Immunogen Inc
IMGN
$25.9M 0.36%
+875,000
New +$17.4M
GLUE icon
34
Monte Rosa Therapeutics
GLUE
$1.33B
$25.6M 0.35%
4,535,000
– –
MRUS
35
DELISTED
Merus
MRUS
$24.4M 0.34%
888,888
+444,444
+100% +$10.4M
TRML
36
DELISTED
Tourmaline Bio
TRML
$22.7M 0.31%
868,407
+818,407
+1,637% +$16.4M
RNAM
37
DELISTED
Avidity Biosciences
RNAM
$22.7M 0.31%
2,510,000
– –
RARE icon
38
Ultragenyx Pharmaceutical
RARE
$2.55B
$16.7M 0.23%
350,000
-1,150,000
-77% -$44.6M
FENC icon
39
Fennec Pharmaceuticals
FENC
$377M
$13.5M 0.19%
1,200,000
– –
NUVL
40
DELISTED
Nuvalent
NUVL
$13.2M 0.18%
178,921
-633,579
-78% -$39.2M
TSHA icon
41
Taysha Gene Therapies
TSHA
$1.82B
$7.71M 0.11%
4,355,555
+430,555
+11% +$858K
WHWK
42
Whitehawk Therapeutics
WHWK
$232M
$5.76M 0.08%
2,849,402
– –
AKRO
43
DELISTED
Akero Therapeutics
AKRO
– –
-555,555
Closed -$28.1M
IMA
44
ImageneBio Inc
IMA
$63.9M
– –
-136,667
Closed -$7.1M
IOBT
45
DELISTED
IO Biotech
IOBT
– –
-2,055,883
Closed -$2.84M
MCRB icon
46
Seres Therapeutics
MCRB
$47.9M
– –
-125,000
Closed -$5.95M
PMVP icon
47
PMV Pharmaceuticals
PMVP
$62.9M
– –
-3,000,000
Closed -$18.4M
QQQ icon
48
PUT
Invesco QQQ Trust
QQQ
$479B
– –
-500,000
Closed -$1.22M
TNGX icon
49
Tango Therapeutics
TNGX
$4.72B
– –
-2,222,222
Closed -$25M
SGEN
50
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-1,759,606
Closed -$373M
1
2
3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Avoro Capital Advisors's Q4 2023 Portfolio in Review

As of Q4 2023, Avoro Capital Advisors held 51 positions worth $7.24B, up 13% from $6.41B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Avoro Capital Advisors withdrew a net $224M in Q4 2023, closing 9 positions and reducing 4 holdings. Its most notable exit was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $810M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 100% a quarter earlier.

Against the trend, Avoro Capital Advisors opened a new position in State Street SPDR S&P Biotech ETF worth $397M.

  • Avoro Capital Advisors's largest Q4 2023 buy was State Street SPDR S&P Biotech ETF: 4,444,444 shares worth $397M.
  • Avoro Capital Advisors added most to Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023, an estimated $190M increase.
  • Avoro Capital Advisors's biggest Q4 2023 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $100M.
  • Avoro Capital Advisors fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2023, selling an estimated $810M.
  • Avoro Capital Advisors's ten largest holdings make up 64% of its $7.24B portfolio in Q4 2023.
  • Avoro Capital Advisors opened 5 new positions and closed 9 in Q4 2023.
  • Avoro Capital Advisors's portfolio value rose 13% quarter-over-quarter to $7.24B.

Based on Avoro Capital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.